Late kidney dysfunction in a kidney transplant recipient

Area of Science:

• Nephrology
• Transplant Immunology
• Immunopathology

Background:

• Traditionally, calcineurin inhibitor toxicity was considered the primary cause of late kidney transplant dysfunction and graft failure.
• Recent research challenges this long-held belief, prompting a re-evaluation of rejection mechanisms.

Observation:

• Peritubular capillary C4d staining in kidney allografts is a key indicator of antibody-mediated injury.
• Biopsy findings support the role of antibody-mediated rejection in late graft dysfunction.

Findings:

• Antibody-mediated rejection is now recognized as a major contributor to late kidney allograft dysfunction and loss.
• De novo donor-specific antibodies develop in 20-30% of kidney transplant patients post-transplant.

Implications:

• The emergence of antibody-mediated rejection as a significant factor necessitates new diagnostic and therapeutic approaches.
• Current treatment strategies are largely off-label, highlighting the need for FDA-approved therapies and rigorous clinical trials for antibody-mediated rejection.